

Patient treatment in the phase II trial completed according to plan

- Treatment of the last patients terminated
- In all, 203 patients were treated at 15 centres
- Results are expected for the beginning of August

Darmstadt, 5th July 2019 – The CytoTools AG (WKN: A0KFRJ; ISIN: DE000A0KFRJ1) reported today that the treatment of the last patients in the phase II trial of DermaPro® were completed at the end of June as planned. Now the process of data preparation and evaluation has begun and is being pursued intensively.

This trial, carried out by the subsidiary DermaTools Biotech GmbH is aimed at establishing the dosages for the coming clinical phase III trial and the European approval of DermaPro®. Up to the end of the treatment period, a total of 203 patients, at 15 centres in four countries, were treated with different active substance concentrations of DermaPro® or a comparator product. Within the scope of the data preparation being carried out currently, the data bank entries of the clinical parameters of the most recently treated patients will be examined for consistency and plausibility. When this process is completed, the statistical evaluation is carried out so that the first results will be available at the beginning of August, from CW 32.

These results form the basis for finalising the design, and the submission of the application, for the coming European phase III trial for DermaPro® in the diabetic foot indication. The application for approval of the subsequent phase III is currently in preparation, so that the submission can take place as soon as the results are available. Furthermore, the selection of suitable additional centres for phase III has begun, so that after the final approval for the trial has been granted, patient recruiting can quickly commence.

This press release contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.



About CytoTools

CytoTools AG is a German biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (62%) and CytoPharma GmbH (50%).

Contact:

CytoTools AG

Dr. Mark Andre Freyberg

CEO

Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: freyberg@cytotools.de

www.cytotools.de

UBJ. GmbH

Ingo Janssen

Haus der Wirtschaft

Kapstadtring 10

D-22297 Hamburg

Tel.: +49-40-6378-5410

Fax.: +49-40-6378-5423

E-Mail: ir@ubj.de